The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.

NCT07234422 | Not Yet Recruiting Phase 3 DMC

• 2 other identifiers: NL87982.042.24METc 2025/02
• Study Type: interventional
• Target: 1,100
• Locations: 1 country
• Sites: 7

Brief Summary

The goal of this clinical trial is to learn whether taking selenium and coenzyme Q10 (CoQ10) can reduce HF related events and deaths related to cardiovascular disease. Researchers will compare selenium-CoQ10 supplements with a placebo to see if the supplements improve heart health and patient outcomes. Participants will: Receive either selenium-CoQ10 or placebo in addition to their usual heart failure treatment Attend standard clinical visits according to routine clinical care. The study will include 1,100 adults with chronic heart failure. Selenium and CoQ10 are natural nutrients with no known health risks. If effective, this supplement could provide a safe new way to improve outcomes for people with heart failure.

Conditions

Heart Failure

Keywords

heart failure; selenium; coQ10; registry based randomized clinical trial

Outcome Measures

Primary Outcomes (1)

• Composite of repeated HF hospitalization, repeated urgent HF visits and cardiovascular death

  Total (first and subsequent) HF hospitalizations, urgent visits for HF visits and cardiovascular deaths with selenium/coQ10 compared to placebo.

  ongoing, up to ~30 months

Secondary Outcomes (3)

• Total number of events of (repeated) HF hospitalization and (repeated) urgent HF visits

  ongoing, up to ~30 months

• Time to death from any cause

  ongoing, up to ~30 months

• Time to cardiovascular death

  ongoing, up to ~30 months

Other Outcomes (4)

• Total number of (repeated) all cause hospitalizations

  ongoing, up to ~30 months

• Total number of (repeated) unscheduled cardiovascular hospital visits

  ongoing, up to ~30 months

• Total days alive out of hospital

  ongoing, up to ~30 months

Study Arms (2)

Selenium/CoQ10

EXPERIMENTAL

Oral dosage of twice daily Selenium/CoQ10 (2 x 100 μg selenium tablets (SelenoPrecise 100 μg, Pharma Nord, Denmark) and 2 x 100 mg Q10 capsules (Bio-Quinon 100 mg B.I.D, Pharma Nord, Denmark)

Dietary Supplement: Selenium/CoQ10

Placebo

PLACEBO COMPARATOR

Drug: Matching Placebo (B)

Interventions

Selenium/CoQ10 DIETARY_SUPPLEMENT

Oral dosage of twice daily Selenium/CoQ10 (2 x 100 μg selenium tablets (SelenoPrecise 100 μg, Pharma Nord, Denmark) and 2 x 100 mg Q10 capsules (Bio-Quinon 100 mg B.I.D, Pharma Nord, Denmark)

Selenium/CoQ10

Matching Placebo (B) DRUG

Matching Placebo

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \>18 years
• Outpatients with chronic HF, NYHA II - ambulatory IV
• Serum NT-proBNP concentrations \>600 pg/mL (71 pmol/L) if in sinus rhythm; \>1000pg/mL (118 pmol/L) if in Atrial fibrillation\*

You may not qualify if:

• History of myocardial infarction, myocarditis, percutaneous intervention, cardiac surgery or stroke \<30 days
• The presence of a mechanical assist device
• Scheduled for mechanical assist device or heart transplant
• Other non-cardiac conditions with limited life expectancy (\<1 year)
• Amyloid, hypertrophic obstructive or constrictive cardiomyopathy
• End stage kidney disease for which chronic intermittent peritoneal or haemodialysis
• Unable to sign informed consent
• (Unwilling to stop) use of over the counter supplements coQ10/selenium
• Peanut and/or soy allergy

Sponsors & Collaborators

• Netherlands Heart Institute: lead
• University Medical Center Groningen: collaborator
• ZonMw: The Netherlands Organisation for Health Research and Development: collaborator
• Hartstichting: collaborator
• Pharma Nord: collaborator
• WCN (Werkgroep Cardiologische centra Nederland): collaborator

Study Sites (7)

Noordwest Ziekenhuisgroep

Alkmaar, Netherlands

Location

AUMC

Amsterdam, Netherlands

Location

Amphia Ziekenhuis

Breda, Netherlands

Location

Catharina ziekenhuis Eindhoven

Eindhoven, Netherlands

Location

TREANT

Emmen, Netherlands

Location

University Medical Center Groningen

Groningen, 9713GZ, Netherlands

Location

St Antonius ziekenhuis

Nieuwegein, Netherlands

Location

Related Publications (5)

• Alehagen U, Johansson P, Bjornstedt M, Rosen A, Dahlstrom U. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol. 2013 Sep 1;167(5):1860-6. doi: 10.1016/j.ijcard.2012.04.156. Epub 2012 May 23.

  PMID: 22626835 BACKGROUND

• Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, Alehagen U, Steurer G, Littarru GP; Q-SYMBIO Study Investigators. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014 Dec;2(6):641-9. doi: 10.1016/j.jchf.2014.06.008. Epub 2014 Oct 1.

  PMID: 25282031 BACKGROUND

• Bomer N, Grote Beverborg N, Hoes MF, Streng KW, Vermeer M, Dokter MM, IJmker J, Anker SD, Cleland JGF, Hillege HL, Lang CC, Ng LL, Samani NJ, Tromp J, van Veldhuisen DJ, Touw DJ, Voors AA, van der Meer P. Selenium and outcome in heart failure. Eur J Heart Fail. 2020 Aug;22(8):1415-1423. doi: 10.1002/ejhf.1644. Epub 2019 Dec 6.

  PMID: 31808274 BACKGROUND

• Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A. 1985 Feb;82(3):901-4. doi: 10.1073/pnas.82.3.901.

  PMID: 3856239 BACKGROUND

• McKeag NA, McKinley MC, Harbinson MT, McGinty A, Neville CE, Woodside JV, McKeown PP. Dietary Micronutrient Intake and Micronutrient Status in Patients With Chronic Stable Heart Failure: An Observational Study. J Cardiovasc Nurs. 2017 Mar/Apr;32(2):148-155. doi: 10.1097/JCN.0000000000000322.

  PMID: 26829748 BACKGROUND

Related Links

• ZonMW project page SELEQT-HF

MeSH Terms

Conditions

Heart Failure

Interventions

Selenium; coenzyme Q10

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Chalcogens; Elements; Inorganic Chemicals; Minerals

Study Officials

• Peter van der Meer, prof dr

  University Medical Center Groningen

  PRINCIPAL INVESTIGATOR

• Jeroen Schaap, MD,PhD

  Amphia Hospital Breda

  PRINCIPAL INVESTIGATOR

Central Study Contacts

SELEQT-HF Study Team

CONTACT

+31 (0)503616161; seleqt-hf@umcg.nl

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 14, 2025
• First Posted: November 18, 2025
• Study Start: May 1, 2026
• Primary Completion (Estimated): December 1, 2030
• Study Completion (Estimated): December 1, 2030
• Last Updated: April 8, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

NL (7)